All right. Welcome back to the 46th Annual TD Cowen Healthcare Conference. Really happy to have the next session here with -- I'm Marc Frahm from the biotech team here at TD Cowen, and we're really ...

The U.S. Food and Drug Administration has declined to approve an additional indication for Zynyz, a cancer therapy developed by Incyte (INCY) and MacroGenics (MGNX), due to issues found at a ...

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 4.2% in the morning session after the company reported underwhelming third-quarter 2025 financial results. The ...

(RTTNews) - Incyte (INCY) announced that the European Commission has approved Zynyz (retifanlimab) in combination with carboplatin and paclitaxel, a platinum-based chemotherapy regimen, for the ...

Evercore ISI analyst maintained a Hold rating on Incyte yesterday and set a price target of $110.00. The company’s shares closed yesterday at $97.33. In addition to Evercore ISI, Incyte also received ...

After the success of Spider-Man: No Way Home in 2021, fans have been anxiously awaiting the fourth movie in the beloved series. In October 2024, Tom Holland, who has played Spider-Man in six Marvel ...

If Peter Parker falls off a New York City skyscraper and no one knows who he is, does he make a sound? Please don’t bother trying to answer that very silly question, because we all know Tom Holland’s ...

On February 27, the U.S. Food and Drug Administration issued a Complete Response Letter for Incyte Corporation’s (NASDAQ:INCY) supplemental Biologics License Application for Zynyz (retifanlimab-dlwr) ...

Incyte ( (INCY)) just unveiled an announcement. On February 27, 2026, the U.S. Food and Drug Administration issued a Complete Response Letter to Incyte for its supplemental Biologics License ...

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and ...